Enliven Therapeutics (NASDAQ:ELVN) Earns Buy Rating from Analysts at BTIG Research

BTIG Research started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a report issued on Friday, MarketBeat.com reports. The firm issued a buy rating and a $42.00 target price on the stock.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird upped their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Stock Up 0.7 %

ELVN opened at $23.15 on Friday. The company has a 50 day moving average of $26.56 and a two-hundred day moving average of $24.16. Enliven Therapeutics has a 52-week low of $10.90 and a 52-week high of $30.03. The company has a market cap of $1.13 billion, a P/E ratio of -12.18 and a beta of 1.02.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 847 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $25,410.00. Following the sale, the insider now directly owns 1,015,188 shares in the company, valued at $30,455,640. The trade was a 0.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 129,195 shares of company stock worth $3,581,772. 29.20% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after acquiring an additional 601,611 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after purchasing an additional 313,019 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after purchasing an additional 67,813 shares during the last quarter. State Street Corp grew its stake in Enliven Therapeutics by 2.9% in the third quarter. State Street Corp now owns 745,944 shares of the company’s stock worth $19,051,000 after purchasing an additional 21,018 shares in the last quarter. Finally, First Turn Management LLC increased its holdings in Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after buying an additional 121,849 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.